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Abstract: Stratiﬁ  cation of cardiac patients arriving at the emergency department is now being made according to the levels 
of acute cardiac biomarkers (i.e. cardiac troponin (cTn) or creatine kinase myocardial band (CK-MB)). Ongoing efforts are 
undertaken in an attempt to identify and validate additional cardiac biomarkers, for example, interleukin-6, soluble CD40L, 
and C-reactive protein, in order to further risk stratify patients with acute coronary syndrome. Several studies have also now 
shown an association of platelet transcriptome and genomic single nucleotide polymorphisms with myocardial infarction 
by using advanced genomic tools. A number of markers, such as myeloid-related protein 14 (MRP-14), cyclooxygenase-1 
(COX-1), 5-lipoxygenase activating protein (FLAP), leukotriene A4 hydrolase (LTA4H) and myocyte enhancing factor 2A 
(MEF2A), have been linked to acute coronary syndromes, including myocardial infarction. In the future, these novel mark-
ers may pave the way toward personalized disease-prevention programs based on a person’s genomic, thrombotic and 
cardiovascular proﬁ  les. Current and future biomarkers and bioassays for identifying at-risk patients will be discussed in this 
review.
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Introduction
Cardiovascular disease claims over 10 million lives annually worldwide. The development of cardiac 
biomarkers has allowed physicians to make life-saving treatment decisions in a safe and cost-effective 
manner by reducing overly-aggressive therapy regimens and nonessential invasive procedures. Cur-
rently, when cardiovascular patients arrive to the emergency department, treatment decisions are guided 
by the medical history, physical examination, electrocardiogram results, and the levels of cardiac-speciﬁ  c 
biomarkers. Due to the sensitivity and speciﬁ  city of cardiac biomarkers, one can rapidly determine the 
level of myocardial necrosis and the risk level of a patient. Plasma biomarkers such as troponin and 
creatine kinase myocardial band (CK-MB) are the frontline markers aiding clinicians in the diagnosis 
of cardiac ischemia. While these cardiac enzymes are invaluable in acute clinical settings for directing 
treatment, their presence only represents a consequence of cardiac events. Recent advances in genom-
ics open up new avenues for identifying genetic risk factors decades before patients develop heart 
disease. Although it is likely to take many more years to develop and validate these genetic markers, 
the successful development of inhibitors to these susceptible genes and gene products would provide 
the prospect of interfering the progression of cardiovascular disease early in development and reduce 
clinical events.
In addition to early identiﬁ  cation of cardiac disease, the monitoring of the response to therapy is also 
crucial in terms of cardiac patient management. For example, the acute biomarker levels, such as tro-
ponin and CK-MB, provide risk stratiﬁ  cation and direct indication of the effectiveness of the treatment 
and the long term prognosis. High levels of these acute cardiac biomarkers are usually associated with 
poor clinical outcome (Lincoff, Bittl et al. 2003; Kastrati, Mehilli et al. 2006). Due to a heterogeneous 
response of cardiac patients to antiplatelet therapies, bioassays are being developed and used to measure 
the level of platelet inhibition to directly evaluate the level of protection these patients are receiving 
from the anti-platelet therapy and to identify patients who would require a more aggressive dosage. In 
this review, some of the current and future biomarkers for identifying at-risk patients and bioassays for 
evaluating the efﬁ  cacy and possibly individual tailoring of anti-platelet therapies will be discussed.294
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Biomarkers for Cardiovascular 
Diseases
Acute biomarkers for diagnosing 
cardiac events
The development of acute cardiac markers has 
provided a way for physicians to promptly deter-
mine the level of myocardial necrosis a patient has 
suffered. This information helps clinicians to make 
decisions on the use of appropriate antithrombotic 
therapies and interventions for patients diagnosed 
with ACS. The biomarkers for myocardial necrosis 
include creatine kinase-myocardial band (CK-MB) 
and cardiac troponin (cTN).
Creatine kinase-myocardial
band (CK-MB)
CK-MB has been a predominant marker for iden-
tifying ACS patients with myocardial necrosis. 
Circulating CK-MB originates from both cardiac 
and skeletal muscle sources and therefore is not 
entirely cardiospeciﬁ  c (Panteghini, 1995). Histori-
cally, CK-MB played an important role for years 
in aiding ACS diagnosis, detecting myocardial 
injury, and prognosis. A large number of studies 
have been published to support the diagnostic and 
prognostic values of CK-MB in acute coronary 
syndrome (ACS) patients. However, recent large 
registries are showing that troponin is more sensi-
tive and associated with increased risk even in 
CK-MB negative ACS patients. In the CRUSADE 
initiative comparing troponin and CK-MB 
(Newby, Roe et al. 2006), there was a discordant 
result in 28% of NSTEMI patients. While 18% 
of the patients had elevated troponin but normal 
CK-MB values, 10% had false-positive CK-MB, 
as deﬁ  ned by normal troponin values. Compared 
to patients who were negative for both markers, 
troponin-positive/CK-MB-negative patients had 
a trend toward increased mortality (4.5% versus 
2.7%). The differences in outcomes could not be 
explained by differences in therapy. Thus, an 
isolated troponin elevation in the setting of nega-
tive CK-MB was associated with increased risk. 
A similar ﬁ  nding has been noted in over 10,000 
ACS patients in the GRACE registry (Goodman, 
Steg et al. 2006). For these reasons, cardiac tro-
ponin (cTn) is currently the preferred assay and 
more commonly used nowadays (Jaffe, Ravkilde 
et al. 2000).
Troponin
Cardiac troponin (cTn) is currently the preferred 
biomarker for the diagnosis and prognosis of acute 
cardiac diseases. Troponin is a cytoskeletal protein 
that consists of three subunits, troponin T (TnT), 
troponin I (TnI) and troponin C (TnC) (Filatov, 
Katrukha et al. 1999). These subunits are present 
in both skeletal muscle and cardiac muscle as dif-
ferent isoforms. Cardiac-speciﬁ  c isoforms of TnT 
(Anderson, Malouf et al. 1991) and TnI (Cummins 
and Perry, 1978) have been identiﬁ  ed. Their tissue 
speciﬁ  cities allow them being highly speciﬁ  c and 
sensitive biomarkers for myocardial injury. In 
contrast, the cardiac isoform of TnC is present in 
both skeletal and cardiac muscles. Non-cardiac 
muscle myopathies can lead to an increase in 
plasma TnC. Therefore, TnC is not used as a spe-
ciﬁ  c marker of cardiac injury (Schreier, Kedes et al. 
1990). Cardiac Tn is present as a cytosolic pool 
and a structural pool. Blood level of cTn increases 
as early as 1 to 10 hours after the onset of cardiac 
injury (Mair, Artner-Dworzak et al. 1991; de 
Winter, Koster et al. 1995). The initial release of 
cTn originates from the cytosolic pool and the 
subsequent release is from the structural pool. This 
increase in plasma cTnT and cTnI levels can be 
detected by current immunoassays. Current assays 
can detect cTn at levels from 0.01 μg/L to 1 μg/L. 
The European Society of Cardiology/American 
College of Cardiology task force has deﬁ  ned the 
upper limit of normal troponin level as the level 
above the 99th percentile in a normal population. 
For making clinical decisions, the troponin level 
is generally used together with 12-lead electrocar-
diogram (ECG) results to stratify patients into risk 
groups when they are being admitted to the hospi-
tal (Savonitto, Ardissino et al. 1999; Braunwald, 
Antman et al. 2002). Troponin level elevation also 
confers an independent prognostic purpose. Eleva-
tion of cTn in ACS patients was correlated with 
increased mortality at 42 days (Antman, Tanasijevic 
et al. 1996).
Most of the patients with ACS do not have ST-
elevation. In these patients, elevated cTn identiﬁ  es 
the subgroup of non-ST elevation myocardial 
infarction (NSTEMI) patients, which are at 
increased risk compared to cTN-negative indi-
viduals (Dokainish, Pillai et al. 2005; Ohtani, Ueda 
et al. 2005; Thom, Haase et al. 2006). Thus, it is 
important to initiate therapy as soon as the diag-
nosis has been made. For this subgroup of NSTEMI 
patients positive in troponin, the use of enoxaparin 295
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in combination with aspirin has been shown to 
reduce the risk of death, myocardial infarction or 
urgent target vessel revascularization by 47% 
within 14 days (Morrow, Antman et al. 2000). 
These cTn-positive NSTEMI patients also respond 
favorably to GPIIb/IIIa antagonists (Newby, 
Ohman et al. 2001) and clopidogrel (Yusuf, Zhao 
et al. 2001). Early invasive interventional strategy 
is also effective in signiﬁ  cantly reducing clinical 
events (Cannon, 2003).
Patients with ST-elevation on ECG and a clini-
cal history suggesting myocardial ischemia and a 
duration of symptoms less than 12 hours should 
receive immediate treatment regardless of cTN 
level. This is because ECG signs for cardiac isch-
emia occur before troponin elevation. Levels of 
troponin elevation in ST-elevation myocardial 
infarction (STEMI) patients had been associated 
with increased risk of short term and long term 
major adverse cardiac events and death (Ohman, 
Armstrong et al. 1996; Stubbs, Collinson et al. 
1996; Gertz, Fallon et al. 1998; Ohman, Armstrong 
et al. 1999; Matetzky, Sharir et al. 2000). Delay in 
seeking medical help after the onset of symptoms 
results in more myocardial damage and elevation 
of troponin level. Studies have shown that patients 
admitted with positive troponin and ST-elevation 
have significantly higher mortality rate than 
patients negative in troponin, which reﬂ  ects the 
adverse effect of delaying treatment. In one of the 
studies, STEMI patients with elevated cTnT 
( 0.1 μg/L) had a mortality rate of 12.5% at 30 
days and 14% at 9 months versus 3.9% and 3.9% 
respectively in patients negative of cTnT (Giannit-
sis, Muller-Bardorff et al. 2001). This group of 
high risk ACS patients should immediately undergo 
an early invasive treatment regimen.
For patients who have undergone percutaneous 
coronary intervention (PCI), a number of studies 
reported that the elevation of post-PCI cTn is asso-
ciated with increased risk of adverse events 
(Morrow, Cannon et al. 2001; Cantor, Newby et al. 
2002; Kizer, Muttrej et al. 2003; Nageh, Sherwood 
et al. 2003). However, a recent study has suggested 
that it is the baseline pre-PCI cTn rather than the 
post-PCI cTn level that is predictive of adverse 
events. They argue that for studies that showed 
elevated cTn post-procedure to be associated with 
adverse events did not take the pre-PCI cTn level 
into consideration when establishing the correlation 
(Miller, Garratt et al. 2006). In their study of 2352 
patients with progressive symptomatic coronary 
artery disease or acute coronary syndrome, 11.1% 
patients with pre-PCI cTn elevation ( 0.3 μg/L) 
suffered from adverse events within a year in com-
parison to only 4.7% of patients without pre-PCI 
cTn elevation and post-PCI cTn level was not pre-
dictive of adverse events when baseline elevation 
was included in the analysis. Yet for patients with-
out increased pre-PCI cTn, post-PCI cTn elevation 
is signiﬁ  cantly predictive of adverse events (Nageh, 
Sherwood et al. 2003; Nageh, Sherwood et al. 
2005). Thus, both pre- and post-PCI cTn level 
appear to be a useful prognostic biomarker under 
different circumstances. Patients who have under-
gone coronary artery bypass grafting (CABG) 
would also have elevated levels of cTn secondary 
to the procedure itself. High level of post-procedure 
cTn after CABG is associated with poor outcomes 
in these patients (Bonnefoy, Filley et al. 1998; 
Carrier, Pellerin et al. 2000).
Patients with chronic renal disease (CRD) often 
have elevated levels of cTnT in the absence of acute 
coronary syndrome (Freda, Tang et al. 2002; De 
Zoysa, 2004). This is because cTnT is renally 
cleared and poor renal function leads to an accu-
mulation of cTnT. One way to determine if a CRD 
patient has ACS is to compare the cTnT level to 
the patient’s previously established baseline level 
if available. Other information such as patients’ 
age, clinical risk factors and ECG should also be 
used to support clinical triage decisions. However, 
in the absence of this critical information, one 
should treat the patient as an ACS patient (Aviles, 
Askari et al. 2002). There are many other clinical 
situations unrelated to cardiac ischemia in which 
cTN level may be elevated. These conditions 
include pericarditis (Bonnefoy, Godon et al. 2000; 
Brandt, Filzmaier et al. 2001), congestive heart 
failure (Missov, Calzolari et al. 1997; Horwich, 
Patel et al. 2003; Perna, Macin et al. 2004), drug 
toxicity (Cardinale, Sandri et al. 2004) and sepsis 
(Ammann, Maggiorini et al. 2003) for example.
In the general population, the cTnT level of 
some individuals is increased. This elevation may 
indicate subclinical cardiac injury. In a general 
population study, plasma cTnT levels of 3557 
subjects were evaluated. cTnT elevation ( 0.01 μg/L) 
was found to be independently correlated with 
congestive heart failure, left ventricular hypertro-
phy, diabetes mellitus and chronic renal diseases 
by multivariable logistic regression analysis 
(Wallace, Abdullah et al. 2006). These data suggest 
that a subject with even a minute increase of cTnT 296
Sim et al
Biomarker Insights 2008:3
may be at increase risk of cardiovascular events. 
Also, the upper limit of normal troponin level 
for the immunoassays should be lower than the 
current 0.01 μg/L in order to better detect at-risk 
patients.
Development of inﬂ  ammatory
biomarkers for predicting upcoming 
cardiac events
A number of inﬂ  ammatory markers have been 
studied for their potential as independent markers 
in detecting risk prior to ACS. Inﬂ  ammatory mark-
ers are often elevated before the occurrence of 
myocardial necrosis. Thus, they may be valuable 
in reporting the risk level of patients who are 
negative for troponin or CK-MB. Patients at risk 
for non-ST-elevation myocardial infarction or 
unstable angina with negative troponin and no or 
atypical symptoms are perfect examples. These 
“at-risk” subjects in the general population who 
have not developed any symptom or atypical 
symptoms may beneﬁ  t from the measurements of 
these markers and triaged to early preventive 
therapies if these markers are elevated. Some of 
the inﬂ  ammatory markers that have been studied 
include interleukin-6 (IL-6), soluble CD40 ligand 
(sCD40L) and C-reactive protein (CRP). The 
elevation of IL-6 within the ﬁ  rst two days of hos-
pitalization in patients with ACS was associated 
with adverse in-hospital outcomes (Biasucci, 
Liuzzo et al. 1999). In a prospective study of 
14,916 healthy males, an association of IL-6 levels 
and myocardial infarction was observed during a 
6-year follow-up period. Of the participants, 202 
subjects developed myocardial infarction with 
signiﬁ  cantly higher level of baseline IL-6 in com-
parison to the matched control subjects (Ridker, 
Rifai et al. 2000). The risk of future myocardial 
infarction was also increased with increasing level 
of IL-6. The elevation of sCD40L is also associated 
with acute coronary syndrome. In a prospective 
study of 28,263 healthy middle-aged American 
women, 130 of them suffered a cardiovascular 
event during a 4-year follow-up. This group was 
found to have a modest yet statistically signiﬁ  cant 
increased baseline sCD40L (2.86 ng/mL) versus 
the 130 age- and smoking- matched subjects 
(2.09 ng/mL, p   0.02) (Schonbeck, Varo et al. 
2001). Of the different inﬂ  ammatory markers, CRP 
probably has received most of the attention. A 
number of studies have found that CRP is a 
powerful independent predictor of future 
cardiovascular risk (Liuzzo, Biasucci et al. 1994; 
Kuller, Tracy et al. 1996; Ridker, Cushman et al. 
1997; Tracy, Lemaitre et al. 1997; Morrow, Rifai 
et al. 1998; Koenig, Sund et al. 1999; Danesh, 
Whincup et al. 2000; Heeschen, Hamm et al. 2000; 
Lindahl, Toss et al. 2000; Ridker, Hennekens et al. 
2000; Lowe, Yarnell et al. 2001; Ridker, Rifai et al. 
2001; Ridker, Stampfer et al. 2001; Mueller, 
Buettner et al. 2002). While it is a strong predictor, 
two recent studies however showed that the addi-
tion of CRP to traditional risk factors did not sig-
niﬁ  cantly improve prediction of cardiovascular 
disease (Cook, Buring et al. 2006; Folsom, 
Chambless et al. 2006). The difﬁ  culty of applying 
these inﬂ  ammatory markers to current clinical 
settings is the event rates associated with elevation 
of these markers are low and there are no clinical 
trials to offer therapeutic guidance in these patients 
with elevated inﬂ  ammatory markers. As a result, 
asymptomatic patients may be advised to be treated 
with often expensive prophalytic therapy unneces-
sarily. Further studies therefore will certainly be 
needed to demonstrate the utility of inﬂ  ammatory 
markers as independent risk factor and how to 
apply them in the clinic. Perhaps, a multi-marker 
approach could be used to risk stratify patients.
Development of transcriptomic
and genomic markers biomarkers
for identifying at-risk patient
and implementing pharmacogenomic 
therapies
The advancement of molecular genetics has ush-
ered in novel approaches to identify cardiovascular 
biomarkers. Two current molecular approaches are 
transcriptomic analysis and genome-wide scanning 
of mRNA and genes associated with the develop-
ment of cardiovascular diseases. A number of 
promising genetic biomarkers have been identiﬁ  ed 
by these techniques.
Platelet transcriptome
The analysis of transcriptome in platelets repre-
sents a potential novel method for identifying 
biomarkers for cardiovascular patients. Human 
platelets possess functional spliceosome, small 
nuclear RNAs, splicing proteins, and endogenous 
pre-mRNAs. Among them are pre-mRNAs for 
cardiovascular-related proteins. Upon platelet 297
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activation and integrin engagement, the spliceosome 
excise the introns in pre-mRNAs to generate the 
mature mRNAs for the translation of the mRNA 
products (Weyrich, Dixon et al. 1998; Lindemann, 
Tolley et al. 2001; Denis, Tolley et al. 2005). 
Therefore, the changes in the mRNA transcripts 
and their products in platelets may serve as bio-
marker for establishing risk factor and prognosis 
for cardiovascular disease. Since coronary throm-
bus formation and platelet activation precedes 
myocardial injury, platelet transcriptome activation 
proﬁ  ling may offer an earlier diagnosis, possibly 
many hours before myocardial injury and troponin 
elevation.
By proﬁ  ling the platelet mRNA from patients 
with STEMI, myeloid-related protein 14 (MRP-14), 
a protein which has been reported to modulate 
calcium signaling, arachidonic acid metabolism, 
cytoskeletal reorganization, and leukocyte trafﬁ  ck-
ing (Donato, 2003; Vogl, Ludwig et al. 2004), 
appeared to be a novel determinant of cardiovas-
cular events (Healy, Pickard et al. 2006). In this 
study, the platelet transcriptome of patients with 
acute ST-elevation (n = 16) was compared to 
patients with stable coronary artery disease 
(n = 44). By microarray analyses, the median 
expression of MRP-14 in STEMI patients was 2.2 
fold higher than control patients with stable coro-
nary artery disease (CAD). With real-time PCR, 
the level of MRP-14 was also 2.2 fold higher in 
STEMI patients. Plasma measurements further 
conﬁ  rmed these ﬁ  ndings. MRP-14 exists as MRP-
8/14 heterodimer in plasma. STEMI patients had 
a plasma MRP-8/14 concentration of 17.0 μg/mL, 
versus 8.0 μg/mL in stable CAD patients (p   0.001). 
In a subsequent prospective study with a median 
follow-up time of 2.9 years, subjects with MRP-
8/14 plasma concentration in the highest quartile 
( 3.36 μg/mL) had a 3.8-fold increase in risk in 
developing a ﬁ  rst cardiovascular event than the 
subjects in the lowest quartile ( 1.15 μg/mL). In 
the same study, the mRNA CD69 was also found 
to be differentially transcripted in STEMI patients 
(Healy, Pickard et al. 2006). However, its potential 
as a biomarker in predicting cardiovascular events 
remained to be explored.
The study of platelet mRNA has also led to the 
ﬁ  nding of de novo synthesis of cycloxygenase-1 
(COX-1) in activated platelets (Evangelista, 
Manarini et al. 2006). The activation of platelets 
leads to the release of arachidonic acid by phos-
pholipase A2 and the formation of thromboxane A2 
(TXA2) by COX-1. The release of TXA2 further 
potentiates platelet activation and aggregation. 
Aspirin inhibits this process by the irreversible 
acetylation of serine-529 on COX-1. In this plate-
let mRNA study, washed platelets with COX-1 
activity inhibited by aspirin regained ability to 
synthesize TXA2 24 hours after being treated with 
thrombin and ﬁ  brinogen (Evangelista, Manarini 
et al. 2006). The authors proposed that platelets 
overcome aspirin inhibition to generate TXA2 by 
the activation-induced de novo synthesis of COX-
1 and hypothesized that this observation as being 
one of the mechanisms for aspirin resistance, espe-
cially for people on low-dose aspirin. They further 
supported their theory by showing that COX-1 
mRNA is present in platelets and the exposure of 
aspirin-treated platelets to thrombin and ﬁ  brinogen 
led to the translation mRNA as evidenced by the 
incorporation of [
35S]-methionine into the newly 
synthesized COX-1 protein. TXA2 is a potent 
platelet activator and only a small amount is neces-
sary to activate platelets. In fact, it has been shown 
that in order to inhibit the platelet activating effect 
of TXA2, aspirin needs to inhibit over 95% of the 
COX-1 activity. Their hypothesis and observation 
may have an implication in terms of individual-
izing aspirin therapy in order to suppress the 
recovery of COX-1 activity caused by de novo 
synthesis. In a clinical study by the same group 
(Sciulli, Renda et al. 2006), platelets from patients 
experiencing CHD generated higher levels of 
TXB2 than healthy subjects even though both 
groups were on low-dose aspirin. Whether there is 
a causal relationship between de novo COX-1 syn-
thesis and high levels of TXB2 in CHD patients 
remained to be elucidated. If de novo COX-1 syn-
thesis is further proven by other studies to be associ-
ated with CHD, COX-1 mRNA may serve as a risk 
biomarker for cardiovascular patients. Of note is that, 
even though a number of studies have identiﬁ  ed 
aspirin resistance patients whose platelets remained 
responsive to agonists after being treated with aspi-
rin (Gum, Kottke-Marchant et al. 2001; Eikelboom, 
Hirsh et al. 2002; Gum, Kottke-Marchant et al. 
2003), the mechanism behind these observations 
remains unclear and controversial with some inves-
tigators believing that the majority of aspirin non-
responsiveness is due to patient non-compliance with 
taking aspirin (Cotter, Shemesh et al. 2004; Dalen, 
2007). Perhaps the observation of de novo synthesis 
COX-1 represents one of the mechanisms causing 
aspirin resistance.298
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Single nucleotide polymorphisms (SNPs) 
as genetic markers implicated in myocardial 
infarction
After the completion of the human genome project, 
much research has been devoted into identifying 
genetic markers for predicting risk of cardiovas-
cular disease. Genome-wide scanning for SNPs in 
genes implicated in coronary disease has been 
pursued by different groups. By scanning the mic-
rosatellite markers distributed in genomes of fami-
lies and siblings, a number of studies have identiﬁ  ed 
the chromosomal location of loci associated with 
cardiovascular disease by linkage analysis.
One of the genes that have been associated to 
cardiovascular disease is 5-lipoxygenase activat-
ing protein (FLAP) (Helgadottir, Manolescu et al. 
2004). In this report, 296 Icelandic families with 
713 individuals with myocardial infarction and 
1741 individuals of their ﬁ  rst-degree relative were 
analyzed. A set of 1068 microsatellites was 
scanned. A 4-SNP haplotype, called HapA, in the 
gene ALOX5AP on chromosome 13q12-13 for 
encoding FLAP was associated with a two times 
greater risk in myocardial infarction and stroke. 
In this study, another 4-SNP haplotype of 
ALOX5AP, called HapB, in the United Kingdom 
population was also associated with a 2 times 
greater risk of myocardial infarction. FLAP regu-
lates the leukotriene biosynthetic pathway that 
results in the generation of leukotriene A4 (LTA4), 
LTB4, LTC4, LTD4, and LTE4. Among these 
leukotrienes, LTB4 is a potent pro-inﬂ  ammatory 
mediator. To determine if the leukotriene pathway 
may be involved in myocardial infarctions, the 
level of LTB4 generation by neutrophils activated 
by ionomycin in individuals with HapA haplotype 
who suffered from myocardial infarction was 
measured. Ionomycin-induced LTB4 level was 
signiﬁ  cantly higher in the MI group than the con-
trol group. Currently, a FLAP inhibitor is being 
developed for the prevention of thrombotic events 
in patients with at-risk haplotype (Hakonarson, 
Thorvaldsson et al. 2005). The success of this trial 
would demonstrate the application of pharmacoge-
nomics and personalized medicine in the ﬁ  eld of 
cardiovascular disease.
LTA4 hydrolase, another protein involved in the 
leukotriene pathway and encoded by the LTAH 
gene, was also found to be associated with myo-
cardial infarction risk by genome-wide scanning 
(Helgadottir, Manolescu et al. 2006). HapK hap-
lotype in the LTAH gene on chromosome 12 
contributes a relative risk of 1.45 and 1.16 for 
myocardial infarction in Icelanders and European 
Americans respectively, whereas HapK confers a 
relative risk of 3.50 in African Americans. This 
observation suggests that the HapK haplotype 
probably interacts with other genetic or environ-
mental risk factors speciﬁ  c to African Americans 
and increases the relative risk of myocardial infarc-
tion in this ethnic group. This haplotype highlights 
how pharmacogenomics can be applied to beneﬁ  t 
a population subgroup. The ethnic speciﬁ  city of 
genetic marker can help clinicians in identifying 
high risk patients by associating genetic biomarker 
with a speciﬁ  c subpopulation background.
A third gene that has been identiﬁ  ed to be asso-
ciated with cardiovascular disease by genome-wide 
scanning is myocyte enhancing factor 2A (MEF2A) 
on chromosome 15q26 (Wang, Fan et al. 2003). 
MEF2A is a member of the myocyte enhancer 
family of transcription factors. A 21-base pair dele-
tion of the stop codon in exon 11 was present in 
all individuals with coronary artery disease in the 
family that was examined. The deletion of the 21 
base pairs results in the removal of 7 amino acids 
in a region that has been demonstrated to be impor-
tant for nuclear localization of the MEF2A. 
Another group recently has reported that subjects 
with a Pro279Leu variant of MEF2A in exon 7 has 
an odds ratio of 3.1 for myocardial infarction 
(Gonzalez, Garcia-Castro et al. 2006). This obser-
vation lends further support to the hypothesis that 
MEF2A is associated with MI.
Before the availability of genome-wide scanning, 
a number of genes associated with myocardial 
infarction have already been identiﬁ  ed by SNPs 
studies. These genes include thrombospondin 4 
(McCarthy, Parker et al. 2004), thrombospondin 2 
(McCarthy, Parker et al. 2004), lymphotoxin-α and 
galectin-2. As genome-wide scanning become 
more common, the discovery rate of disease-
causing genes will be certainly accelerated. 
Although this method offers a powerful and unbi-
ased method in identifying genes implicated in 
cardiovascular disease, the results need to be 
interpreted with caution. The penetrance of cardio-
vascular risk confers by a particular mutation in a 
gene is often modulated by other genetic and envi-
ronmental factors. Thus, a high risk factor in one 
population may not always manifest as such in 
another population, for example, the HapK haplo-
type of LTA4 hydrolase. The use of genetic 
biomarkers not only provides a novel way in 299
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identifying at-risk patients but has the potential of 
tailoring a gene-speciﬁ  c therapeutic regimen for 
these patients.
Bioassays for Evaluating
the Efﬁ  cacy of Cardiovascular 
Therapies
Different individuals respond to antithrombotic 
drugs differently. Bioassays that can evaluate the 
efﬁ  cacy of cardiovascular drug regimen in patients 
would ensure they are all receiving the desired 
therapeutic effect despite differences in their 
genetic makeup. This is crucial not only for deter-
mining the efﬁ  cacious dose of antithrombotic drugs 
for an individual in an acute setting but also for 
prophylactic protection. Therefore, an efﬁ  cacy 
assay which is predictive of clinical outcome 
should be an integral part of patient management 
as its impact would be more direct and immediate. 
Current antithrombotic therapies include the use 
of antiplatelet agents and anticoagulants. While 
these drugs have provided immense beneﬁ  ts for 
many patients, a signiﬁ  cant number of patients 
received insufﬁ  cient protection from these drugs, 
as illustrated by the SYNERGY trial. In this trial, 
high risk patients with acute coronary syndrome 
were treated with the best known combination of 
antithrombotic drugs. Yet 14% of the patients still 
experienced death or myocardial infarction within 
the ﬁ  rst 30 days (Ferguson, Califf et al. 2004) and 
17.6% within the ﬁ  rst 6 months (Mahaffey, Cohen 
et al. 2005). With better monitoring of antithrom-
botic therapy, perhaps one could identify patients 
who would require more aggressive or alternative 
treatments before events occurred.
The two most commonly used antiplatelet drugs 
for chronic treatment are aspirin and clopidogrel. 
Their targets, COX-1 and P2Y12 respectively, are 
known to be important in platelet activation and 
thrombus formation. In recent studies, it has 
become apparent that a portion of patients are 
resistant to these drugs and more prone to adverse 
clinical events. Based on ADP- and arachidonic 
acid-induced platelet aggregation, 5.2% of stable 
patients with cardiovascular disease (n = 326) were 
found to be aspirin-resistant. This group had a 3-
fold increase in death, myocardial infarction, or 
cerebrovascular accident (Gum, Kottke-Marchant 
et al. 2003). In another aspirin-resistance study of 
patients (n = 976) at high risk for cardiovascular 
events, patients with upper quartile serum TXB2 
levels were more likely to suffer an MI (OR = 2) 
or cardiovascular death (OR = 3.5) than patients 
in the lower quartile (Eikelboom, Hirsh et al. 
2002). Clopidogrel-resistance is also prevalent 
among cardiovascular patients. In one study, ADP-
induced platelet aggregation, GPIIb/IIIa activation 
and P-selectin expression were used to evaluate 
the efﬁ  cacy of clopidogrel. Thirty one percent and 
15% of the PCI patients were non-responsive to 
clopidogrel therapy 5 and 30 days after PCI respec-
tively (Gurbel, Bliden et al. 2003). In another study 
of PCI patients (n = 60), patients in the upper 
quartile of clopidogrel resistance, based on ADP-
induced aggregation, have a 40% event rate within 
6 months compared to none in patients who are 
responsive to clopidogrel (Matezky S et al. Circ, 
2004 109:3171). Patients resistant to both aspirin 
and clopidiogrel have also been identiﬁ  ed (Lev, 
Patel et al. 2006). In a group of PCI patients, 12.7% 
and 24% of the patients (n = 150) were found to 
be aspirin- and clopidogrel-resistant, respectively. 
Of the aspirin-resistant patients, 47.4% of them 
were also resistant to clopidogrel. This collection 
of studies highlights the frequency of aspirin- and 
clopidogrel-resistance in a clinical setting and how 
bioassays would help clinicians in identifying 
therapy-resistant patients who are not receiving the 
intended therapeutic beneﬁ  t from these drugs. Cur-
rently, for the detection of aspirin-resistant patients, 
collagen-, ADP-, and arachidonic acid (AA)-
induced platelet aggregation, Ultegra VerifyNow 
Aspirin assay, serum TXB2 level, urinary TXB2, 
and PFA-100 platelet function analyzer have been 
used. For the detection of clopidogrel-resistant 
patients, ADP-induced platelet aggregation and 
Ultegra VerifyNow P2Y12 assay have been uti-
lized. However, these assays remain to be validated 
prospectively with clinical outcomes.
While these bioassays can evaluate the efﬁ  cacy 
of aspirin or clopidogrel therapy, they are only 
effective in monitoring one speciﬁ  c platelet activa-
tion pathway at a time. However, current anti-
thrombotic therapies involve the inhibition of 
multiple pathways by multiple drugs, for example, 
the combination of aspirin and clopidogrel. Thus, 
multiple assays need to be performed. This way is 
not only laborious and time-consuming in a clini-
cal setting but also ineffective in providing a global 
physiological analysis of the antithrombotic effect 
of the combination therapies. Therefore, an optimal 
assay should be sensitive to detect all the affected 
thrombosis pathways concomitantly.300
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Thrombosis is usually initiated by the exposure 
of prothrombotic stimuli on the injured vessel wall 
or ruptured plaque to the blood ﬂ  ow. Platelets then 
accumulate at the lesion site and form a thrombus. 
The growth of thrombus in the coronary artery may 
lead to a reduction or stoppage of blood ﬂ  ow to 
cause myocardial ischemia. Aspirin and clopido-
grel combination prevent occlusive thrombi not 
only by inhibiting platelet activation but also by 
promoting thrombus destabilization. Therefore, it 
will be clinically useful and optimal to have a 
bioassay for monitoring the efﬁ  cacy of these drugs 
alone or in combination, for continuous monitoring 
of the thrombus formation and thrombus destabi-
lization process, especially in patients presenting 
with acute myocardial infarction. The measure-
ment of thrombus formation in a perfusion cham-
ber coated with prothrombotic stimuli may 
represent an optimal bioassay (Sakariassen, Joss 
et al. 1990; Andre, Arbeille et al. 1996; Sakariassen, 
Hanson et al. 2001). By ﬂ  uorescently labeling 
platelets, and coupling the assay to a computerized 
real-time monitoring system, continuous measure-
ment of platelet adhesion to a prothrombotic sur-
face, thrombus propagation, and thrombus stability 
would become feasible. The adaptation of this 
technique into an easy to use format may provide 
a new clinical assay for monitoring the efﬁ  cacy of 
these antithrombotic drugs in patient.
Summary
Cardiac troponin is currently the preferred bio-
marker for evaluating the degree of myocardial 
damage a patient has sustained. The use of tropo-
nin together with other diagnostic tools has allowed 
physicians to prescribe early proper treatment for 
patients with ACS. While the current cTn immu-
noassays are useful for diagnosing and saving 
patients in an acute setting, clinicians do not yet 
have a way to identify otherwise currently healthy 
subjects who would suffer from ACS in their 
future. Perhaps, the recent identiﬁ  cation of genetic 
markers may remedy the situation. Subjects car-
rying the susceptible haplotypes could be identiﬁ  ed 
years before any cardiovascular disease develops. 
The successful validation of these markers would 
allow the practice of personalized pharmacoge-
nomics in the cardiovascular disease area. One day, 
physicians might be able to prescribe personalized 
disease-prevention program based on a person’s 
genome. In the future, with new genetic tools for 
screening high-risk patients, acute biomarkers for 
determining myocardial damage and novel bioas-
says for monitoring drug efﬁ  cacy, we will be able 
to better identify, monitor, and treat patients with 
acute coronary syndrome.
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